Dr Javad Nazarian
University Children’s Hospital, Zurich, Switzerland. George Washington University and Children’s National Medical Center in Washington, D.C.
Doctors Beroukhim and Nazarian present their work on how chromatin modifications and aneuploidy are involved in DIPG and the wider implications in other cancers.
Alterations in chromosome structure, both at the chromatin level and in the form of aneuploidy, are a central feature of cancers in general and DIPG specifically. In this webinar, we will discuss two projects that look at different aspects of these changes. Mutations in histone encoding genes were initially discovered in DIPG; Dr. Nazarian will discuss data that extend these findings to other related proteins and cancers and their implications for chromatin and genomic stability. Dr. Beroukhim will then discuss the implications of the genomic instability that results, describing methods to determine the selective pressures that shape large-scale aneuploidies across cancers.
Date: Thursday 22 April 2021
Time: 3.00pm BST
Duration: 1 hour 15 minutes
Overview of the webinar
Click to find out more about out our speakers
Head of DMG Research Center at University Children’s Hospital, Zurich Switzerland, and an Associate Professor of Pediatrics at the George Washington University and Children’s National Medical Center in Washington, D.C.
In his role, Dr. Nazarian has formed national and international collaborations in an effort to establish a translational and multi-disciplinary team focusing on childhood high grade gliomas.
Dr. Nazarian’s research focus has been understanding the molecular pathways driving childhood brain cancers and, most importantly, finding ways for rapid translation of laboratory findings to the clinic. He has extensive expertise in forming and leading national and international collaborations, and in disease/pathway-focused team building. His research groups in Zurich and at Children’s National Medical Center in Washington DC, focus on developing biorepositories, disease preclinical models, performing molecular analyses, drug assays, and correlative studies for ongoing clinical trials. Working in close collaboration with Pacific Pediatric Neuro-Oncology Consortium (PNOC), Dr. Nazarian has established a working group encompassing 16 international institutions across North America, Europe and Australia. The primary goal of the team is to generate hypothesis derived preclinical data, test across institutions, validate using multiple preclinical DMG models, and provide input to the clinical team. The team’s goal is to accelerate the discovery of clinically translatable therapies for the treatment of childhood brain cancers.
A state-of-the-art platform for speakers to engage with the UK and international neuro-oncology community, where presenting our new data has directly led to several potential future collaborations which will move our research forward even faster.
If you’ve any questions, or would like to present your data at one of our future webinars, please contact the Research team on email@example.com or call +44 (0)1252 418190.